Public Summary

Summary for ARTG Entry:	276956 Bromelain Forte
ARTG entry for	Medicine Listed
Sponsor	Herbs of Gold Pty Ltd
Postal Address	PO Box 3143, KIRRAWEE, NSW, 2232 Australia
ARTG Start Date	24/06/2016
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Bromelain Forte

Product Type Single Medicine Product **Effective Date** 29/08/2019

Permitted Indications

Anti-inflammatory/relieve inflammation

Aid/assist in the healing of minor body tissue injuries

Relieve mild tissue oedema

Decrease/reduce/relieve symptoms of soft tissue trauma

Linked indication - Analgesic/Anodyne/relieve pain
Linked indication - Relieve mild tissue oedema

Maintain/support healthy digestion

Aid/assist/helps digestion of (state nutrient)

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information	
Pack Size	**Poison Schedule**

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	

Active Ingredients

bromelains	**18 million PU**

Other Ingredients (Excipients)

hypromellose
maltodextrin
medium chain triglycerides
purified water
Rice bran

Public Summary